Skip to content
value.today
Proteon Therapeutics Inc. logo

Proteon Therapeutics Inc.

Total raised
$49 M
3 rounds on record
Latest round
$30 M
May 2014
First round on record
Aug 2011
Today
Went public
See the company page

Proteon Therapeutics Inc. is listed today as Protara Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Proteon Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2017$22 MPrivate placement after listing$10 to $50 million

Proteon Therapeutics Inc.: Private sale, Aug 2017

Investors in this round

11 investors had bought by the notice of Aug 16, 2017: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Proteon Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series A Convertible Preferred Stock which is convertible into Common Stock, $.001 par value.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel P. Gottlieb · Executive Officer · Mr. Gottlieb is the Vice President of Corporate Development of the Issuer.
  • E. Scott Toner · Executive Officer · Mr. Toner is the Senior Vice President of Marketing of the Issuer.
  • George A. Eldridge · Executive Officer · Mr. Eldridge is the Chief Financial Officer, Senior Vice President, Treasurer and Assistant Secretary of the Issuer.
  • Matthew P. Kowalsky · Executive Officer · Mr. Kowalsky is the Vice President of Legal and the Secretary of the Issuer.
  • Steven K. Burke, M.D. · Executive Officer · Dr. Burke is a Senior Vice President and the Chief Medical Officer of the Issuer.
  • Timothy P. Noyes · Executive Officer, Director · Mr. Noyes is the President and Chief Executive Officer of the Issuer.
  • Garen J. Bohlin · Director
  • Hubert J. Birner, Ph. D. · Director
  • John G. Freund, M.D. · Director
  • Jonathan G. Leff · Director
  • Paul J. Hastings · Director
  • Scott A. Canute · Director
  • Tim G. Haines · Director
  • Tony G. Kingsley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by George A. Eldridge, Sr. V.P. and Chief Financial Officer of the Issuer. Source: SEC Form D, newest notice filed Aug 16, 2017. Read the notice at the SEC.

equity, optionsSEC
May 2014$30 MNo. 3$10 to $50 million

Proteon Therapeutics Inc.: Raise no. 3, May 2014

Investors in this round

22 investors had bought by the notice of May 28, 2014: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Proteon Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel P. Gottlieb · Executive Officer
  • George P. Eldridge · Executive Officer
  • Steven K. Burke · Executive Officer
  • Timothy Noyes · Executive Officer, Director
  • Brendan Nicholas O'Leary · Director
  • Dmitry D. Kobyzev · Director
  • F. Nicholas Franano · Director
  • Gregory D. Phelps · Director
  • Hubert D. Birner · Director
  • John G. Freund · Director
  • Tim D. Haines · Director
  • Todd D. Foley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by President/CEO, Timothy P. Noyes. Source: SEC Form D, newest notice filed May 28, 2014. Read the notice at the SEC.

equitySEC
Sep 2013$4 MNo. 2$2 to $10 million

Proteon Therapeutics Inc.: Raise no. 2, Sep 2013

Investors in this round

17 investors had bought by the notice of Feb 19, 2014: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Proteon Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dean D. Profis · Executive Officer
  • Timothy Noyes · Executive Officer, Director
  • Brendan Nicholas O'Leary · Director
  • F. Nicholas Franano · Director
  • Gregory D. Phelps · Director
  • Hubert D. Birner · Director
  • Stephen D. Hoffman · Director
  • Todd D. Foley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Timothy P. Noyes, President and CEO. Source: SEC Form D, newest notice filed Feb 19, 2014. Read the notice at the SEC.

equity, debt, optionsSEC
Aug 2011$15 MNo. 1$10 to $50 million

Proteon Therapeutics Inc.: Raise no. 1, Aug 2011

Investors in this round

19 investors had bought by the notice of Aug 11, 2011: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Proteon Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dean G. Profis · Executive Officer
  • Timothy Noyes · Executive Officer, Director
  • Brendan Nicholas O'Leary · Director
  • David G. Lowe · Director
  • F. Nicholas Franano · Director
  • Gregory D. Phelps · Director
  • Hubert G. Birner · Director
  • Steven G. St. Peter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Timothy Noyes, President. Source: SEC Form D, newest notice filed Aug 11, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Proteon Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2017).

    SEC Form D · Aug 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2017

That is all the official record says: Proteon Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Proteon Therapeutics Inc. are on record.

Investors#

19 named in official filings. Open an investor to see everything it has backed.

Investors in Proteon Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Abingworth LLPFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield International Master Fund, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Deerfield Mgmt IV, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Deerfield Partners, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Deerfield Private Design Fund IV, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, director (Form 3, 2017)SEC Form 3
Deerfield Special Situations International Master Fund, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Pharmstandard International S.A.Companynot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Prism Venture Partners V-A LPVenture capitalnot statednot statedHeld Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Prism Venture Partners V L.P.Venture capitalnot statednot statedHeld Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Public Joint Stock Co PharmstandardOthernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Skyline Venture Management IV, LLCVenture capitalnot statednot statedHeld Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Skyline Venture Partners Qualified Purchaser Fund IV L.P.Venture capitalnot statednot statedHeld Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
TVM Life Science Ventures VI GmbH & Co KGVenture capitalnot statednot statedHeld Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
TVM Life Science Ventures VI LPVenture capitalnot statednot statedHeld Series A, A-1, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.

Largest shareholders today

Institutions holding Protara Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Proteon Therapeutics Inc.
NameRoleNamed in
Daniel P. GottliebMr. Gottlieb is the Vice President of Corporate Development of the Issuer.Aug 2017
E. Scott TonerMr. Toner is the Senior Vice President of Marketing of the Issuer.Aug 2017
George A. EldridgeMr. Eldridge is the Chief Financial Officer, Senior Vice President, Treasurer and Assistant Secretary of the Issuer.Aug 2017
Matthew P. KowalskyMr. Kowalsky is the Vice President of Legal and the Secretary of the Issuer.Aug 2017
Steven K. Burke, M.D.Dr. Burke is a Senior Vice President and the Chief Medical Officer of the Issuer.Aug 2017
Timothy P. NoyesMr. Noyes is the President and Chief Executive Officer of the Issuer.Aug 2017
George P. EldridgeExecutive officerMay 2014
Steven K. BurkeExecutive officerMay 2014
Timothy NoyesExecutive officerMay 2014
Dean D. ProfisExecutive officerFeb 2014
Dean G. ProfisExecutive officerAug 2011
Garen J. BohlinDirectorAug 2017
Hubert J. Birner, Ph. D.DirectorAug 2017
John G. Freund, M.D.DirectorAug 2017
Jonathan G. LeffDirectorAug 2017
Paul J. HastingsDirectorAug 2017
Scott A. CanuteDirectorAug 2017
Tim G. HainesDirectorAug 2017
Timothy P. NoyesMr. Noyes is the President and Chief Executive Officer of the Issuer.Aug 2017
Tony G. KingsleyDirectorAug 2017
Brendan Nicholas O'LearyDirectorMay 2014
Dmitry D. KobyzevDirectorMay 2014
F. Nicholas FrananoDirectorMay 2014
Gregory D. PhelpsDirectorMay 2014
Hubert D. BirnerDirectorMay 2014
John G. FreundDirectorMay 2014
Tim D. HainesDirectorMay 2014
Timothy NoyesDirectorMay 2014
Todd D. FoleyDirectorMay 2014
Stephen D. HoffmanDirectorFeb 2014
David G. LoweDirectorAug 2011
Hubert G. BirnerDirectorAug 2011
Steven G. St. PeterDirectorAug 2011

About

American pharmaceutical company.

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.